CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Founder Shares
On November 29, 2017, our sponsor purchased 8,625,000 shares of our Class F common stock for $25,000. In January 2018, our sponsor surrendered 1,437,500 of such shares to the Company for no consideration, resulting in an aggregate of 7,187,500 shares of Class F common stock outstanding, up to 937,500 of which were subject to forfeiture to the extent that the over-allotment option granted to the underwriters of our initial public offering was not exercised within 45 days from March 7, 2019, the effective date of our registration statement. In April 2019, such over-allotment option expired, and as a result our sponsor forfeited 937,500 shares of Class F common stock, resulting in an aggregate of 6,250,000 shares of Class F common stock outstanding.
The holders of our Class F common stock have agreed, subject to limited exceptions, not to transfer, assign or sell such shares until the earlier to occur of (A) one year after the completion of our initial business combination or (B) subsequent to our initial business combination, (x) if the last sale price of the Company’s Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after our initial business combination, or (y) the date on which the Company completes a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of the Company’s stockholders having the right to exchange their shares of Common Stock for cash, securities or other property.
Private Placement Warrants
Our sponsor purchased an aggregate of 7,000,000 warrants (the “Private Placement Warrants”) at a price of $1.00 per warrant, or $7,000,000 in the aggregate, in a private placement that occurred simultaneously with the closing of our initial public offering. Each Private Placement Warrant is exercisable to purchase one share of Class A common stock at a price of $11.50 per share, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like and for certain issuances of equity or equity-linked securities. Private Placement Warrants may be exercised only for a whole number of shares. The Private Placement Warrants (including the Class A common stock issuable upon exercise of the Private Placement Warrants) may not, subject to certain limited exceptions, be transferred, assigned or sold until 30 days after the completion of our initial business combination.
Second Amended and Restated Forward Purchase Agreement
We have entered into a forward purchase agreement pursuant to which, as amended and restated, Crescent Capital, in its capacity as investment advisor to one or more investment funds or accounts (the “Crescent Funds”), has committed, on behalf of the Crescent Funds, to purchase, subject to the terms and conditions set forth in such agreement as described below, an aggregate of 5,000,000 shares of our Class A common stock and 1,666,6662∕3 warrants for an aggregate purchase price of $50,000,000 in a private placement that will close simultaneously with the closing of our initial business combination. Crescent Capital will allocate such purchase obligation, prior to the announcement of our initial business combination, to a particular Crescent Fund or Crescent Funds or otherwise to third party assignees, subject to compliance with applicable securities laws.
The sale of these securities will, if the relevant conditions are satisfied, result in additional gross proceeds available to us for the consummation of our initial business combination and to pay related fees and expenses. To the extent that we obtain alternative financing to fund our initial business combination, the aggregate commitment under the forward purchase agreement will be reduced by the amount of such alternative financing.
Crescent Capital will allocate the obligation to purchase the securities to a Crescent Fund if and only if, as applicable: (i) the investment has been approved by the investment committee, board of directors and/or limited partner advisory board of such Crescent Fund; and (ii) the initial business combination shall be consummated with a company engaged in a business that is within the investment objectives, guidelines and restrictions of such Crescent Fund and not in violation of any conflicts of interest provisions applicable to such Crescent Fund or to Crescent Capital. Crescent Capital will not be committed or obligated to purchase any securities pursuant to the forward purchase agreement if none of the Crescent Funds are able to purchase any such securities due to the conditions described above, unless Crescent Capital expressly agrees in writing to do so. The obligations of the purchasers to the securities are, among other things, conditioned on a requirement that such initial business combination is approved by a unanimous vote of the Board.